CapsoVision Secures \$14 Million in Private Placement, Reports Preliminary 2025 Results

Key Highlights for Investors

• CapsoVision, Inc. (NASDAQ: CV) completed a \$14 million private placement financing, selling approximately 2.87 million shares at \$4.88 per share — a 5% discount to the March 16, 2026, closing price.
• Preliminary, unaudited financial results for Q4 and FY 2025:
  • Q4 2025 revenue: \$3.9 million
  • Full year 2025 revenue: \$13.6 million
  • Year-end (Dec 31, 2025) cash, cash equivalents, restricted cash, and investments: approximately \$10.1 million
• Proceeds from the financing will be used for general corporate purposes, including R&D, sales and marketing, general administration, and working capital.
• CapsoVision’s product pipeline continues to advance, with a focus on new AI-enabled capsule endoscopy solutions, including CapsoCam Colon and CapsoCam UGI.

Details of the Private Placement

CapsoVision closed a \$14 million private placement with selected accredited investors on March 16, 2026. The company issued 2,867,089 shares of common stock at a price of \$4.88 per share, reflecting a 5% discount to the closing price on March 16, 2026. The offering was structured as a PIPE (private investment in public equity) transaction and was not registered under the Securities Act of 1933. The shares were sold under Section 4(a)(2) and Rule 506 of Regulation D, exclusively to accredited investors.

Importantly for shareholders, CapsoVision has agreed to file a registration statement with the SEC within 90 days of the closing to cover the resale of these shares. The Benchmark Company, LLC, and Roth Capital Partners served as financial advisors for the deal.

Shareholder Impact: The issuance of additional shares at a discount may result in some dilution for existing shareholders, but the capital raised is intended to fuel further product development, commercialization efforts, and strengthen the company’s financial position.

Use of Proceeds

Management stated that the proceeds will be allocated to:

• Sales and marketing initiatives
• Research and development, with an emphasis on advancing CapsoCam Colon, CapsoCam UGI, and enhanced AI diagnostic capabilities
• General and administrative expenses
• Working capital to support ongoing operations

CEO Johnny Wang emphasized that the financing reflects investor confidence in CapsoVision’s platform and long-term opportunity. The company is committed to disciplined execution and delivering sustainable, long-term value for shareholders.

Preliminary 2025 Financial Results

CapsoVision released selected unaudited figures for Q4 and FY 2025:

• Q4 2025 revenue: \$3.9 million
• FY 2025 revenue: \$13.6 million
• Cash, cash equivalents, restricted cash, and investments (as of Dec 31, 2025): \$10.1 million

The company will release its full, audited results after market close on March 26, 2026, followed by a conference call and webcast to discuss results and provide a corporate update.

Product Pipeline and Growth Strategy

CapsoVision is a commercial-stage medtech company focused on advanced imaging and AI-enabled capsule endoscopy solutions for gastrointestinal disease detection. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope for small bowel visualization. The next-generation pipeline includes:

• CapsoCam Colon with enhanced AI: Designed for non-invasive colon imaging and polyp detection
• CapsoCam UGI: Targeting non-invasive upper gastrointestinal imaging
• Expansion to additional GI indications: Including esophageal and pancreatic disorders

Forward-Looking Statements and Risks

The press release contains forward-looking statements about expected future performance, development timelines, regulatory submissions, and the use of proceeds. These are subject to significant risks, including market conditions, regulatory clearances, product adaptation for new indications, and general financial health. Investors should consult the latest SEC filings, including the company’s registration statements and risk factors, for a full assessment of risks.

Potential Share Price Impacts

• Positive: Successful financing at a relatively small discount, strengthened cash reserves, and a clear plan to accelerate R&D and commercialization could be viewed favorably by investors.
• Negative: Dilution from the new share issuance, potential delays in product development or regulatory approvals, and any negative surprises in the final audited results could impact sentiment.
• Key Date: March 26, 2026, when full audited results and management commentary will be released.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with their financial advisors before making investment decisions. The information herein is based on preliminary, unaudited results and forward-looking statements that are subject to risks and uncertainties.

View CapsoVision, Inc Historical chart here